Background & Trial Rationale in LMICs
- Antenatal corticosteroids (ACS) accelerate fetal lung maturity, enhance surfactant production, and reduce neonatal mortality in preterm infants.
- Evidence in high-resource countries showed consistent reductions in respiratory distress syndrome (RDS), intraventricular hemorrhage, and neonatal death.
- In 2014, the Antenatal Corticosteroid Trial (ACT Trial, Lancet) evaluated ACS roll-out across low-resource settings and unexpectedly reported an increased neonatal mortality (RR 1.12) and increased maternal infection rates.
- The adverse outcomes in the ACT trial occurred because accurate ultrasound dating was absent (many term pregnancies were exposed) and delivery occurred in primary units lacking basic newborn resuscitation facilities.
- This trial created widespread clinical hesitancy in developing countries regarding the safety of scaling up ACS.
The WHO ACTION-I Trial (NEJM 2020)
- The World Health Organization launched the ACTION-I trial (Antenatal Corticosteroids for Improving Outcomes in preterm Newborns) to establish safety and efficacy in low-resource settings.
- Design: Multi-country, randomized, double-blind, placebo-controlled trial across 29 hospitals in India, Bangladesh, Kenya, Nigeria, and Pakistan.
- Participants: 2,852 women with singleton or multiple pregnancies at 26 weeks 0 days to 33 weeks 6 days of gestation with imminent risk of preterm birth.
- Mandatory trial safeguards:
- Accurate gestational age confirmed by early ultrasound.
- True high likelihood of imminent preterm birth.
- Delivery at facilities with basic neonatal care capacity (resuscitation, thermal control, CPAP, feeding support, and oxygen).
- Intervention: Intramuscular Dexamethasone (6 mg IM every 12 hours for up to 4 doses; total 24 mg) versus identical placebo.
Findings Of The ACTION-I Trial
| Clinical Outcome | Dexamethasone Group | Placebo Group | Relative Risk (95% CI) | Statistical Significance |
|---|---|---|---|---|
| Neonatal Death | 19.6% | 23.5% | RR 0.84 (0.72–0.97) | 16% mortality reduction ($p=0.03$) |
| Stillbirth Or Neonatal Death | 25.7% | 29.2% | RR 0.88 (0.78–0.99) | 12% reduction ($p=0.04$) |
| Need For Respiratory Support | 43.1% | 51.5% | RR 0.84 (0.76–0.93) | Significant reduction in RDS |
| Maternal Sepsis Or Infection | 2.5% | 3.3% | RR 0.76 (0.50–1.17) | No increase in maternal infection |
| Suspected Neonatal Sepsis | 10.1% | 10.3% | RR 0.98 (0.78–1.24) | No increase in neonatal infection |
- The trial proved that dexamethasone saves approximately 4 neonatal lives per 100 women treated when given under proper dating and neonatal care conditions.
The ACTION-III Trial (Late Preterm)
- The US ALPS trial (2016) showed that late preterm steroids (34 to 36 weeks) reduced transient tachypnea and RDS, but doubled the risk of neonatal hypoglycemia.
- The WHO ACTION-III trial is evaluating the efficacy, safety, and cost-effectiveness of antenatal corticosteroids specifically in the late preterm window (34+0 to 36+6 weeks) in low- and middle-income countries.
- The trial examines whether neonatal respiratory benefits justify the risks of neonatal hypoglycemia in settings with limited bedside blood glucose monitoring.
Dexamethasone vs Betamethasone Regimens
| Parameter | Dexamethasone Sodium Phosphate | Betamethasone (Phosphate + Acetate) |
|---|---|---|
| Standard Dose | 6 mg IM every 12 hours $\times$ 4 doses (total 24 mg) | 12 mg IM every 24 hours $\times$ 2 doses (total 24 mg) |
| Formulation Type | Single short-acting preparation | Mixture of rapid phosphate + slow-release depot acetate |
| Availability In India | Readily available, inexpensive, heat-stable | Costlier, occasional cold-chain supply issues |
| ACTION-I Validation | Directly proven in the landmark ACTION-I trial | Historic standard in high-income settings |
WHO 2022 Implementation Criteria
The updated WHO 2022 guidelines recommend ACS for women at risk of preterm birth from 24 to 34 weeks only when all four prerequisites are met:
- Accurate gestational age is confirmed (preferably by early ultrasound).
- Preterm birth is considered imminent within the next 48 hours to 7 days.
- There is no clinical evidence of maternal infection (such as chorioamnionitis).
- Adequate neonatal care is available at the delivery center (resuscitation, warmth, CPAP, and oxygen).
Repeat Courses And Precautions
- A single rescue course (12 mg $\times 2$ doses or 6 mg $\times 4$ doses) can be given if more than 7 days have passed since the first course, gestational age remains <34 weeks, and delivery is again imminent within 7 days.
- Routine multiple repeat courses (>2 courses) are contraindicated because they cause fetal growth restriction, microcephaly, and adverse neurodevelopment.
- In preterm premature rupture of membranes (PPROM), ACS is indicated up to 34 weeks in the absence of chorioamnionitis.
- In twin or multiple pregnancies, the standard dose (24 mg total) is given; the dose is not doubled.